Summary

Global Dysmenorrhea Treatment Market was valued at USD 5.73 million in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.36% through 2030. Dysmenorrhea is a common gynecological condition characterized by severe menstrual pain and cramps experienced by many women during their menstrual cycle. The global dysmenorrhea treatment market refers to pharmaceutical and healthcare products and services aimed at addressing and alleviating the symptoms of dysmenorrhea. The global dysmenorrhea treatment market is driven by several key factors. The rising prevalence of menstrual disorders, particularly dysmenorrhea, among women worldwide is a major growth driver. Increased awareness about menstrual health and growing healthcare expenditures have led to higher demand for effective treatment options, including pain relievers, hormonal therapies, and alternative medicine. Advances in pharmaceutical research and the development of novel nonsteroidal anti-inflammatory drugs (NSAIDs) and hormonal contraceptives further boost market expansion. Additionally, the increasing adoption of telemedicine and e-pharmacies facilitates easier access to treatment solutions. Government initiatives promoting women’s health, coupled with growing support from non-profit organizations, contribute to market growth. The rising preference for natural and herbal remedies also drives innovation in dysmenorrhea treatment products. Moreover, a shift towards personalized medicine and the expansion of healthcare infrastructure in emerging economies present lucrative opportunities for market players, fostering overall market growth.
Key Market Drivers
Growing Female Population
The global dysmenorrhea treatment market has been on a steady rise, and one of the key factors driving its growth is the continuously expanding female population. Dysmenorrhea, commonly known as menstrual cramps, affects women of all ages, and as the global female population increases, so does the potential demand for effective treatments. For instance, a March 2022 study published in BMC Women's Health found that 92.3% (1,107 women) experienced primary dysmenorrhea (non-pathological), while 7.7% (92 women) had secondary dysmenorrhea (pathological). These findings highlight the high prevalence of menstrual pain among women, emphasizing the need for better management strategies and awareness of underlying conditions causing secondary dysmenorrhea.
Dysmenorrhea is a prevalent gynecological condition characterized by severe menstrual pain and cramps. It affects women during their reproductive years, and as the female population grows, so does the number of individuals at risk of experiencing dysmenorrhea. This increased prevalence directly correlates with a higher demand for dysmenorrhea treatment options.
Key Market Challenges
Stigma and Taboos
One of the primary challenges in addressing dysmenorrhea is the persistence of stigma and cultural taboos surrounding menstruation. In many societies, menstruation remains a taboo subject, making it difficult for women to openly discuss their symptoms and seek appropriate treatment. This cultural barrier can deter women from seeking medical help and contribute to delayed diagnosis and treatment.
Key Market Trends
Non-Pharmacological Approaches
While pharmaceuticals have traditionally been the go-to treatment for dysmenorrhea, there is a growing interest in non-pharmacological approaches. These include physical therapies, such as yoga and acupuncture, dietary modifications, and lifestyle changes. As women seek holistic and natural solutions, these alternative therapies are likely to gain prominence.
Key Market Players
• Novartis AG
• Bayer AG
• Abbott Laboratories Inc.
• F Hoffmann-La Roche AG
• Sanofi SA
• Pfizer Inc.
• GSK PLC
• Johnson & Johnson
• Alvogen Inc.
• AbbVie Inc.

Report Scope:
In this report, the Global Dysmenorrhea Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
• Dysmenorrhea Treatment Market, By Type:
o Primary Dysmenorrhea
o Secondary Dysmenorrhea
• Dysmenorrhea Treatment Market, By Treatment:
o Medication
o Surgery
o Therapy
• Dysmenorrhea Treatment Market, By End-Users:
o Hospitals & Clinics
o Ambulatory Care Centers
o Others
• Dysmenorrhea Treatment Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ Germany
§ United Kingdom
§ France
§ Italy
§ Spain
o Asia-Pacific
§ China
§ Japan
§ India
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
§ Kuwait
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Dysmenorrhea Treatment Market.
Available Customizations:
Global Dysmenorrhea Treatment market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Dysmenorrhea Treatment Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type (Primary Dysmenorrhea, Secondary Dysmenorrhea)
5.2.2. By Treatment (Medication, Surgery, Therapy)
5.2.3. By End-Users (Hospitals & Clinics, Ambulatory Care Centers, Others)
5.2.4. By Region
5.2.5. By Company (2024)
5.3. Product Market Map
5.3.1. By Type
5.3.2. By Treatment
5.3.3. By End-Users
5.3.4. By Region
6. North America Dysmenorrhea Treatment Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type (Primary Dysmenorrhea, Secondary Dysmenorrhea)
6.2.2. By Treatment (Medication, Surgery, Therapy)
6.2.3. By End-Users (Hospitals & Clinics, Ambulatory Care Centers, Others)
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Dysmenorrhea Treatment Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type
6.3.1.2.2. By Treatment
6.3.1.2.3. By End-Users
6.3.2. Canada Dysmenorrhea Treatment Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type
6.3.2.2.2. By Treatment
6.3.2.2.3. By End-Users
6.3.3. Mexico Dysmenorrhea Treatment Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type
6.3.3.2.2. By Treatment
6.3.3.2.3. By End-Users
7. Europe Dysmenorrhea Treatment Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type (Primary Dysmenorrhea, Secondary Dysmenorrhea)
7.2.2. By Treatment (Medication, Surgery, Therapy)
7.2.3. By End-Users (Hospitals & Clinics, Ambulatory Care Centers, Others)
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Dysmenorrhea Treatment Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Treatment
7.3.1.2.3. By End-Users
7.3.2. United Kingdom Dysmenorrhea Treatment Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Treatment
7.3.2.2.3. By End-Users
7.3.3. France Dysmenorrhea Treatment Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Treatment
7.3.3.2.3. By End-Users
7.3.4. Italy Dysmenorrhea Treatment Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type
7.3.4.2.2. By Treatment
7.3.4.2.3. By End-Users
7.3.5. Spain Dysmenorrhea Treatment Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type
7.3.5.2.2. By Treatment
7.3.5.2.3. By End-Users
8. Asia-Pacific Dysmenorrhea Treatment Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type (Primary Dysmenorrhea, Secondary Dysmenorrhea)
8.2.2. By Treatment (Medication, Surgery, Therapy)
8.2.3. By End-Users (Hospitals & Clinics, Ambulatory Care Centers, Others)
8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Dysmenorrhea Treatment Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Treatment
8.3.1.2.3. By End-Users
8.3.2. Japan Dysmenorrhea Treatment Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Treatment
8.3.2.2.3. By End-Users
8.3.3. India Dysmenorrhea Treatment Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Treatment
8.3.3.2.3. By End-Users
8.3.4. Australia Dysmenorrhea Treatment Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type
8.3.4.2.2. By Treatment
8.3.4.2.3. By End-Users
8.3.5. South Korea Dysmenorrhea Treatment Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type
8.3.5.2.2. By Treatment
8.3.5.2.3. By End-Users
9. South America Dysmenorrhea Treatment Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type (Primary Dysmenorrhea, Secondary Dysmenorrhea)
9.2.2. By Treatment (Medication, Surgery, Therapy)
9.2.3. By End-Users (Hospitals & Clinics, Ambulatory Care Centers, Others)
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Dysmenorrhea Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Treatment
9.3.1.2.3. By End-Users
9.3.2. Argentina Dysmenorrhea Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Treatment
9.3.2.2.3. By End-Users
9.3.3. Colombia Dysmenorrhea Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Treatment
9.3.3.2.3. By End-Users
10. Middle East and Africa Dysmenorrhea Treatment Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type (Primary Dysmenorrhea, Secondary Dysmenorrhea)
10.2.2. By Treatment (Medication, Surgery, Therapy)
10.2.3. By End-Users (Hospitals & Clinics, Ambulatory Care Centers, Others)
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Dysmenorrhea Treatment Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By Treatment
10.3.1.2.3. By End-Users
10.3.2. Saudi Arabia Dysmenorrhea Treatment Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By Treatment
10.3.2.2.3. By End-Users
10.3.3. UAE Dysmenorrhea Treatment Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By Treatment
10.3.3.2.3. By End-Users
10.3.4. Kuwait Dysmenorrhea Treatment Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Type
10.3.4.2.2. By Treatment
10.3.4.2.3. By End-Users
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches
13. Porter’s Five Forces Analysis
13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Products
14. Competitive Landscape
14.1. Novartis AG
14.1.1. Business Overview
14.1.2. Product Offerings
14.1.3. Recent Developments
14.1.4. Financials (As Reported)
14.1.5. Key Personnel
14.1.6. SWOT Analysis
14.2. Bayer AG
14.3. Abbott Laboratories Inc
14.4. F Hoffmann-La Roche AG
14.5. Sanofi SA
14.6. Pfizer Inc
14.7. GSK PLC
14.8. Johnson & Johnson
14.9. Alvogen Inc
14.10. AbbVie Inc.
15. Strategic Recommendations
16. About Us & Disclaimer